Business

This archive collects stories about businesses — from startups and local enterprises to multinational corporations — taking meaningful action on social, environmental, and economic challenges. These reports highlight moments when commerce and accountability intersect in constructive ways.

Brain model, for article on glioblastoma vaccine

Vaccine prolongs life of patients with aggressive brain cancer in new trial

By / / Good News For Humankind

Glioblastoma patients now have the most promising new treatment in nearly three decades, after a personalised vaccine more than doubled five-year survival rates in a large international trial. The vaccine works by extracting proteins from a patient’s own tumour and combining them with their white blood cells, training the immune system to recognise and destroy the cancer — with benefits seen even among those traditionally considered hardest to treat. If regulators approve it, this could signal a new era of personalised immunotherapy for cancers that have long resisted every available option.

Rolls-Royce & easyJet hydrogen engine, for article on hydrogen jet engine

World’s first test run of a hydrogen jet engine proves a success

By / / Good News For Humankind

Hydrogen-powered flight moved from theory to reality when Rolls-Royce and easyJet successfully ran a modern jet engine on green hydrogen produced entirely from wind and tidal energy. Unlike battery-electric approaches, hydrogen burns clean — releasing water vapor instead of carbon dioxide — and this test proved a real engine can handle it. Aviation has been one of the hardest sectors to decarbonize, so a confirmed proof of concept opens a genuine path forward. Every major breakthrough in flight history started exactly here: on the ground, with an engine, and a question that finally got answered.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment, for article on psilocybin therapy

The world’s first Phase 3 psilocybin clinical trial is about to commence

By / / Good News For Humankind

Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.

Injecting vaccine, for article on India HPV vaccine

Indian company develops country’s first HPV vaccine

By / / Good News For Humankind

CERVAVAC, India’s first homegrown cervical cancer vaccine, is priced at just $2.50 to $5.00 per dose — a fraction of what HPV vaccines have cost in wealthy countries for nearly two decades. Developed by the Serum Institute of India, it protects against the HPV strains responsible for the majority of cervical cancers worldwide, and the company aims to produce around 200 million doses in its first two years. Cervical cancer is almost entirely preventable, yet it still kills hundreds of thousands of women each year, mostly in lower-income countries where vaccines have been priced out of reach. An affordable, locally made option doesn’t just change the math for India — it points toward a future where health tools belong to the people who need them most.